Some cookies are essential to the running of the website, while others (analytics) help us to make improvements. We also incorporate functionality from other websites, such as video, social media feeds and ReachDeck (text-to-speech and translations services) which may set cookies. More on how we use cookies
This website uses text-to-speech software called ReachDeck to read and / or translate its content. To use ReachDeck, you must allow ReachDeck cookies; the ReachDeck icon will then appear at the bottom right of your screen.
You can find out more about how ReachDeck uses cookies or change your cookie preferences at any time by going to our cookies page.
Allow ReachDeck cookies Do not use ReachDeck
Please find service updates and current visiting rules in our COVID-19 section.
This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.
She has been particularly interested in the role of B cells in Common Variable Immunodeficiency (CVID). Along with others, she showed that CVID patients have few peripheral blood memory B cells and has published translational methodology describing the phenotyping of memory B cells to be carried out in routine clinical immunology departments and the laboratory was one of the leading groups in a European effort to establish a validated classification system to phenotype peripheral blood cells in this disease. The research group continues to explore disease related gene expression in CVID that may contribute to disease phenotype/susceptibility; including examination of proteins such as Alpha-1 antitrypsin, Nod-2 and polymorphisms of CD45. In addition, they retain an interest in the wider diagnostic approach to patients with antibody immunodeficiency and an ELISA detecting IgG Antibodies to Salmonella as a means of replacing test immunisation in antibody deficiency patients has been developed by the Binding Site company and the laboratory are ollaborating in a Europe Wide trial to determine if Salmonella test immunisation can replace the current pneumococcal test immunisation in these patients. The department actively participates in the initial diagnosis and work up of some very rare immunodeficiencies, including Severe Combined Immunodeficiencies [SCID] and complement deficiencies.
As an NHS translational immunology department we are committed to continually applying methods that we have developed or new assays that we have introduced to examine diseases such as mesothelioma, autoimmune pancreatitis, primary biliary cirrhosis, and cardiovascular disease. Through NIHR grants we are exploring the optimization and implementation of microparticle detection assays and T cell functional assays into a routine laboratory with a view to using these assays to contribute significantly to the early diagnosis of different aspects of chronic diseases such as CVID, Rheumatoid arthritis and Cardiovascular disease.
Phenotyping panels for
Biomarkers of inflammation
Functional microparticle measurement
Functional T cell assays
More Developmental Assays that we are happy to discuss include